[干酪乳杆菌YIT 8018（LC 9018）与多种抗肿瘤药物联合使用时抗肿瘤活性的增强]
[Augmentation of antitumor activity of Lactobacillus casei YIT 8018 (LC 9018) in combination with various antitumor drugs].
作者信息
Matsuzaki T, Kato I, Yokokura T, Mutai M
出版信息
Gan To Kagaku Ryoho. 1984 Mar;11(3):445-51.
Augmentation of antitumor activity of Lactobacillus casei YIT 9018 (LC 9018), which strongly inhibits the growth of transplantable allogeneic and syngeneic mouse tumors, in combination with antitumor drugs was investigated. Antitumor drugs used in this study were cyclophosphamide (CY), mitomycin C (MMC), 5-fluorouracil (5-FU) and bleomycin (BLM). The antitumor activity of LC 9018 was augmented by combining 5-FU, MMC or BLM against subcutaneously implanted Meth A and BLM, 5-FU or CY against subcutaneously implanted Sarcoma 180 respectively. Furthermore, combinations with BLM, CY, MMC or 5-FU, BLM, CY, MMC significantly inhibited the growth of intraperitoneally inoculated Meth A or Sarcoma 180, respectively. The combination therapy of LC 9018 with CY significantly prolonged the life span of L 1210-inoculated mouse, while the treatment with LC 9018 alone had no inhibitory effect on L 1210. It was suggested that augmentation of antitumor activity of LC 9018 in combination with CY was due to the inhibition of decrease in the number of peritoneal exudate cells caused by CY injection.
研究了与抗肿瘤药物联合使用时，对可移植的同种异体和同基因小鼠肿瘤生长有强烈抑制作用的干酪乳杆菌YIT 9018（LC 9018）的抗肿瘤活性增强情况。本研究中使用的抗肿瘤药物有环磷酰胺（CY）、丝裂霉素C（MMC）、5-氟尿嘧啶（5-FU）和博来霉素（BLM）。分别联合5-FU、MMC或BLM时，LC 9018对皮下接种的Meth A肿瘤的抗肿瘤活性增强；联合BLM、5-FU或CY时，LC 9018对皮下接种的肉瘤180肿瘤的抗肿瘤活性增强。此外，分别联合BLM、CY、MMC或5-FU、BLM、CY、MMC时，能显著抑制腹腔接种的Meth A或肉瘤180的生长。LC 9018与CY的联合治疗显著延长了接种L 1210的小鼠的寿命，而单独使用LC 9018治疗对L 1210没有抑制作用。提示LC 9018与CY联合时抗肿瘤活性增强是由于抑制了CY注射引起的腹腔渗出细胞数量减少。
Zotero 插件